A5033698551- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Cancer, Lipids, and Metabolism
- Metabolomics and Mass Spectrometry Studies
- Ovarian cancer diagnosis and treatment
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Treatments and Mutations
- Breast Lesions and Carcinomas
- PARP inhibition in cancer therapy
- Estrogen and related hormone effects
- Immunotherapy and Immune Responses
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Caveolin-1 and cellular processes
- Peptidase Inhibition and Analysis
- BRCA gene mutations in cancer
- Monoclonal and Polyclonal Antibodies Research
- Cancer-related Molecular Pathways
- PI3K/AKT/mTOR signaling in cancer
- Molecular Biology Techniques and Applications
Philipps University of Marburg
2019-2025
Universitätsklinikum Gießen und Marburg
2019-2024
Universität Hamburg
2011-2024
University Hospital Heidelberg
2013-2024
Heidelberg University
2012-2024
University Medical Center Hamburg-Eppendorf
2011-2024
University of Rostock
2016-2024
University Hospital Ulm
2018-2024
University Hospital and Clinics
2024
Agaplesion Markus Hospital
2013-2024
Purpose The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain. Methods Tumor at surgery association with long-term outcome 6,377 patients primary receiving neoadjuvant anthracycline-taxane–based chemotherapy seven randomized trials were analyzed. Results Disease-free (DFS) was significantly superior no invasive situ residuals or nodes (n = 955) compared residual ductal carcinoma only 309), but...
Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients early triple-negative breast cancer. Whether the addition of to neoadjuvant chemotherapy would significantly increase percentage cancer who have a pathological complete response (defined as no invasive negative nodes) at definitive surgery is unclear.
PURPOSE Preclinical data suggest a contribution of the immune system to chemotherapy response. In this study, we investigated prespecified hypothesis that presence lymphocytic infiltrate in cancer tissue predicts response neoadjuvant chemotherapy. METHODS We intratumoral and stromal lymphocytes total 1,058 pretherapeutic breast core biopsies from two anthracycline/taxane-based studies (GeparDuo, n = 218, training cohort; GeparTrio, 840, validation cohort). Molecular parameters lymphocyte...
Gene or protein expression data are usually represented by metric at least ordinal variables. In order to translate a continuous variable into clinical decision, it is necessary determine cutoff point and stratify patients two groups each requiring different kind of treatment. Currently, there no standard method software for biomarker determination. Therefore, we developed Cutoff Finder, bundle optimization visualization methods determination that accessible online. While one the based...
Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity human epidermal growth factor receptor 2 (HER2) –positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) immunologically relevant genes neoadjuvant GeparSixto trial. Patients Methods investigated effect adding carboplatin (Cb) to an anthracycline-plus-taxane combination (PM) on pathologic complete response...
Purpose The aim of the current study was to conduct a pooled analysis studies that have investigated prognostic value tumor-infiltrating lymphocytes (TILs) in early-stage triple negative breast cancer (TNBC). Methods Participating had evaluated percentage infiltration stromally located TILs (sTILs) were quantified same manner patient diagnostic samples TNBC treated with anthracycline-based chemotherapy or without taxanes. Cox proportional hazards regression models stratified by trial used...
The 16th St. Gallen International Breast Cancer Conference 2019 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer.
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor A, has shown clinical efficacy in patients with human epidermal receptor 2 (HER2)–negative metastatic breast cancer. We evaluated the efficacy, measured according to rate of pathological complete response (absence invasive and intraductal disease axillary lymph nodes), safety adding bevacizumab neoadjuvant chemotherapy early-stage
<h3>Importance</h3> The presence of tumor-infiltrating lymphocytes (TILs) is associated with improved outcomes in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer treated adjuvant trastuzumab and chemotherapy. prognostic associations the neoadjuvant setting other anti-HER2 agents combinations are unknown. <h3>Objective</h3> To determine between TILs, pathological complete response (pCR), event-free survival (EFS) end points patients trastuzumab, lapatinib, or...
Abstract Activation of lipid metabolism is an early event in carcinogenesis and a central hallmark many cancers. However, the precise molecular composition lipids tumors remains generally poorly characterized. The aim present study was to analyze global profiles breast cancer, integrate results protein expression, validate findings by functional experiments. Comprehensive lipidomics conducted 267 human tissues using ultraperformance liquid chromatography/ mass spectrometry. products de novo...
Abstract Purpose: Tumor-infiltrating lymphocytes (TIL) in the residual disease (RD) of triple-negative breast cancers (TNBC) after neoadjuvant chemotherapy (NAC) are associated with improved survival, but insight into tumor cell-autonomous molecular pathways affecting these features lacking. Experimental Design: We analyzed TILs RD clinically and molecularly characterized TNBCs NAC explored therapeutic strategies targeting combinations MEK inhibitors PD-1/PD-L1–targeted immunotherapy mouse...
Abstract Ki67 immunohistochemistry (IHC), commonly used as a proliferation marker in breast cancer, has limited value for treatment decisions due to questionable analytical validity. The International Breast Cancer Working Group (IKWG) consensus meeting, held October 2019, assessed the current evidence IHC validity and clinical utility including series of scoring studies IKWG conducted on centrally stained tissues. Consensus observations recommendations are: 1) estrogen receptor HER2...